Earnings History Data for UroGen Pharma Ltd. (URGN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

UroGen Pharma Ltd.

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
06-11-2024	PM		URGN	UroGen Pharma Ltd.	502.42	-0.55	-0.84	-0.68	UroGen Pharma GAAP EPS of -$0.55 beats by $0.26, revenue of $25.2M beats by $1M [11/6/2024 8:02 AM]	12.22	0.01 (0.12%)	13.20	0.99 (8.11%)	10.60 - 20.70	599,938	480,000	468
UroGen Pharma Q3 2024 Earnings Preview [11/5/2024 11:20 AM] UroGen Pharma GAAP EPS of -$0.55 beats by $0.26, revenue of $25.2M beats by $1M [11/6/2024 8:02 AM] UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 [2024-11-06 08:00AM] UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference [Nov-05-24 08:00AM]
13-08-2024	PM		URGN	Urogen Pharma	352.00	-0.91	-0.82	0.00	UroGen Pharma misses top-line and bottom-line estimates; lowers FY24 outlook [8/13/2024 8:04 AM]	14.89	0.38 (2.62%)	14.00	-0.51 (-3.51%)	10.60 - 24.13	771,369	310,000	25,006
UroGen Pharma misses top-line and bottom-line estimates; lowers FY24 outlook [8/13/2024 8:04 AM]
13-05-2024	PM		URGN	UroGen Pharma Ltd.	442.56	-0.97	-0.93	-1.30	UroGen Pharma GAAP EPS of -$0.97 misses by $0.08, revenue of $18.78M misses by $2.61M [5/13/2024 8:06 AM]	13.09	0.35 (2.75%)	12.00	-0.74 (-5.81%)	8.69 - 24.13	538,079	250,000	1,127
UroGen Pharma GAAP EPS of -$0.97 misses by $0.08, revenue of $18.78M misses by $2.61M [5/13/2024 8:06 AM]
14-03-2024	PM		URGN	UroGen Pharma Ltd.	543.86	-0.72	-0.67	-1.22	UroGen Pharma reports mixed Q4 results; initiates FY24 outlook [3/14/2024 8:26 AM]	14.32	-3.15 (-18.03%)	0.0	0.0 (0.00%)	7.75 - 24.13	583,111	270,000	0
UroGen Pharma Q4 2023 Earnings Preview [3/13/2024 11:07 AM] UroGen Pharma reports mixed Q4 results; initiates FY24 outlook [3/14/2024 8:26 AM]
14-11-2023	PM		URGN	UroGen Pharma Ltd.	347.04	-0.68	-0.89	-1.13	UroGen Pharma GAAP EPS of -$0.68 beats by $0.17, revenue of $20.85M beats by $0.82M [11/14/2023 8:18 AM]	11.63	-0.13 (-1.11%)	0.0	0.0 (0.00%)	7.07 - 24.13	275,998	240,000	0
UroGen Pharma GAAP EPS of -$0.68 beats by $0.17, revenue of $20.85M beats by $0.82M [11/14/2023 8:18 AM]
10-08-2023	PM		URGN	UroGen Pharma Ltd.	488.70	-1.03	-1.13	-1.18	UroGen Pharma GAAP EPS of -$1.03 beats by $0.10, revenue of $21.14M beats by $1.02M [8/10/2023 8:02 AM]	21.15	0.45 (2.17%)	21.80	1.10 (5.31%)	6.87 - 23.93	452,359	2,440,000	3,511
UroGen Pharma GAAP EPS of -$1.03 beats by $0.10, revenue of $21.14M beats by $1.02M [8/10/2023 8:02 AM]
11-05-2023	PM	8:00 AM ET (May 11)	URGN	UroGen Pharma Ltd.	280.11	-1.30	-1.39	-1.25	UroGen Pharma GAAP EPS of -$1.30 beats by $0.01, revenue of $17.19M beats by $0.1M [5/11/2023 8:21 AM]	12.40	0.90 (7.83%)	0.0	0.0 (0.00%)	4.85 - 16.11	199,684	430,000	0
UroGen Pharma GAAP EPS of -$1.30 beats by $0.01, revenue of $17.19M beats by $0.1M [5/11/2023 8:21 AM]
16-03-2023	PM	8:00 AM ET (Mar 16)	URGN	UroGen Pharma Ltd.	228.13	-1.22	-1.12	-1.27	UroGen Pharma GAAP EPS of -$1.22 misses by $0.14, revenue of $18.09M misses by $0.42M [3/16/2023 8:03 AM]	9.28	-0.35 (-3.63%)	0.0	0.0 (0.00%)	4.85 - 12.63	117,228	70,000	0
UroGen Pharma GAAP EPS of -$1.22 misses by $0.14, revenue of $18.09M misses by $0.42M [3/16/2023 8:03 AM]
10-11-2022	PM	8:00 AM ET (Nov 10)	URGN	UroGen Pharma Ltd.	270.16	-1.13	-1.22	-1.35	UroGen Pharma GAAP EPS of -$1.13 beats by $0.05, revenue of $16.1M misses by $4.05M [11/10/2022 8:39 AM]	9.12	-1.85 (-16.86%)	9.50	-1.47 (-13.40%)	4.85 - 19.37	219,941	50,000	5,335
UroGen Pharma GAAP EPS of -$1.13 beats by $0.05, revenue of $16.1M misses by $4.05M [11/10/2022 8:39 AM] UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments [Nov-10-22 08:00AM] UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors [Nov-09-22 08:00AM]
11-08-2022	PM	9:00 AM ET (Aug 11)	URGN	UroGen Pharma Ltd.	189.94	-1.18	-1.33	-1.17	UroGen Pharma GAAP EPS of -$1.18 beats by $0.12, revenue of $16.6M misses by $0.68M, reaffirms FY revenue guidance [8/11/2022 8:03 AM]	8.24	-0.66 (-7.46%)	8.91	0.0 (0.00%)	4.85 - 19.66	60,566	50,000	437
UroGen Pharma GAAP EPS of -$1.18 beats by $0.12, revenue of $16.6M misses by $0.68M, reaffirms FY revenue guidance [8/11/2022 8:03 AM] UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments [Aug-11-22 08:00AM]
10-05-2022	PM	8:00 AM ET (May 10)	URGN	UroGen Pharma Ltd.	140.90	-1.25	-1.36	-1.17	UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M [5/10/2022 9:10 AM]	6.35	0.15 (2.42%)	6.02	-0.18 (-2.90%)	5.61 - 19.66	118,119	138,091	500
UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M [5/10/2022 9:10 AM] Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates [May-09-22 06:15PM] Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates [May-10-22 08:00AM] UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments [May-10-22 09:00AM] Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates [May-10-22 10:15AM]
21-03-2022	PM	8:00 AM ET (Mar 21)	URGN	Urogen Pharma	0.00	-1.27	-1.18	0.00	UroGen Pharma GAAP EPS of -$1.27 misses by $0.07, revenue of $16.17M misses by $0.32M [3/21/2022 8:03 AM]	9.04	0.03 (0.33%)	9.31	0.30 (3.33%)	5.61 - 21.29	193,746	132,583	8,000
UroGen Pharma GAAP EPS of -$1.27 misses by $0.07, revenue of $16.17M misses by $0.32M [3/21/2022 8:03 AM] UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments [Mar-21-22 08:00AM] Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates [Mar-21-22 09:15AM]
15-11-2021	PM	8:00 AM ET (Nov 15)	URGN	UroGen Pharma Ltd.	420.65	-1.35	-1.26	-1.31	UroGen Pharma EPS misses by $0.06, misses on revenue [11/15/2021 8:09 AM]	14.73	-4.40 (-23.00%)	19.13	0.0 (0.00%)	14.19 - 28.20	225,099	110,000	1,362
UroGen Pharma EPS misses by $0.06, misses on revenue [11/15/2021 8:09 AM] UroGen Pharma slips on Q3 earnings miss and disappointing guidance [11/15/2021 12:50 PM] UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments [Nov-15-21 08:00AM] Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates [Nov-15-21 12:25PM]
04-08-2021	PM	7:30 AM ET (Aug 4)	URGN	UroGen Pharma Ltd.	345.63	-1.17	-1.10	-1.44	UroGen Pharma EPS in-line, beats on revenue [8/4/2021 8:08 AM]	15.30	-0.41 (-2.61%)	15.30	0.0 (0.00%)	14.61 - 28.20	308,695	130,000	2,758
UroGen Pharma EPS in-line, beats on revenue [8/4/2021 8:08 AM] UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments [Aug-04-21 08:00AM] UROGEN PHARMA (URGN) Reports Q2 Loss, Tops Revenue Estimates [Aug-04-21 09:15AM]
13-05-2021	PM	8:00 AM ET (May 13)	URGN	UroGen Pharma Ltd.	406.28	-1.17	-1.26	-1.79	UroGen Pharma EPS beats by $0.10, misses on revenue [5/13/2021 7:35 AM]	15.38	-2.78 (-15.31%)	15.37	-0.01 (-0.07%)	14.66 - 30.89	495,317	90,000	131
UroGen Pharma EPS beats by $0.10, misses on revenue [5/13/2021 7:35 AM] How Much Are UroGen Pharma Ltd. (NASDAQ:URGN) Insiders Spending On Buying Shares? [May-12-21 08:11AM] UroGen Pharma Ltd. to Host Earnings Call [May-13-21 06:30AM] UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments [May-13-21 07:30AM] UROGEN PHARMA (URGN) Reports Q1 Loss, Misses Revenue Estimates [May-13-21 12:11PM]
18-03-2021	PM	8:00 AM ET (Mar 18)	URGN	UroGen Pharma Ltd.	432.80	-1.38	-1.31	-1.86	UroGen Pharma EPS misses by $0.01, beats on revenue [3/18/2021 8:05 AM]	18.04	-1.46 (-7.49%)	20.99	1.49 (7.64%)	13.12 - 30.89	386,086	270,000	2,790
UroGen Pharma EPS misses by $0.01, beats on revenue [3/18/2021 8:05 AM] UroGen Pharma to receive $75M non-dilutive funding from RTW Investments [3/18/2021 8:15 AM] UroGen Pharma Ltd. to Host Earnings Call [Mar-18-21 06:30AM] UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments [Mar-18-21 07:30AM] UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments [Mar-18-21 08:00AM] UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates [Mar-18-21 09:15AM] UroGen Pharma: Q4 Earnings Insights [Mar-18-21 08:17AM]
09-11-2020	PM	8:00 AM ET (Nov 9)	URGN	UroGen Pharma Ltd.	560.07	-1.31	-1.47	-1.06	UroGen Pharma EPS beats by $0.15, beats on revenue [11/9/2020 8:01 AM]	24.75	1.04 (4.39%)	23.71	0.0 (0.00%)	13.12 - 35.21	126,612	143,563	1,677

10-08-2020	PM	8:00 AM ET (Aug 10)	URGN	UroGen Pharma Ltd.	496.61	-1.44	-1.55	-1.08	UroGen Pharma EPS beats by $0.14, beats on revenue [8/10/2020 8:04 AM]	26.15	2.99 (12.91%)	23.16	0.0 (0.00%)	13.12 - 37.08	221,864	102,557	4,168